StockUS listing USCRBPNASDAQHealthcareEarnings Deterioration

Corbus Pharmaceuticals Holding(CRBP) Stock Analysis | Healthcare

USD --+0.00%
Reward40Moderate
Risk72High
75%Data
Revenue down 100% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 42.45M
Reward Ratingⓘ40 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ72 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CRBP to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Corbus Pharmaceuticals Holding?

, a clinical stage company, develops and commercializes therapeutics for cancer and obesity.

AI Brief Pro

The brief on Corbus Pharmaceuticals Holding

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Corbus Pharmaceuticals Holding?

, a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 42.45M.

Financial Highlights

Investment Breakdown

Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta2.785
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
2427,000 shares
$1.8M
0
3-6months
538,238 shares
$365k
316,100 shares
$126k
6-9months
16,097 shares
$51k
0
9-12months
655,148 shares
$541k
0